Modified alginates for anti-fibrotic materials and applications
AssigneesMassachusetts Institute of Technology, Children's Medical Center Corporation
InventorsArturo Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
Life of this patent
Estimating the term…
Abstract
Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
Claims23
-32. (canceled)
A composition comprising a preparation of alginate capsules encapsulating mammalian cells,
- wherein at least 95% of the capsules in the preparation have a diameter between 1 mm and 4 mm, inclusive,
- wherein the capsules comprise a singularly modified alginate polymer comprising one or more covalently modified monomers defined by Formula I
- wherein —X—R1 is selected from the group consisting of:
Dependencies are inferred from the claim text.